Straits Times Index
3,347.29 +10.70 (+0.32%) Nikkei
38,923.03 +435.13 (+1.13%) Hang Seng
18,454.95 +375.34 (+2.08%) FTSE 100
8,275.38 0.00 (0.00%) Bitcoin USD
69,076.21 +1,286.21 (+1.90%) CMC Crypto 200
1,490.60 +22.66 (+1.54%)
Kintara Therapeutics, Inc. (KTRA)
After hours:
| Previous close | 0.3170 |
| Open | 0.2705 |
| Bid | 0.3025 x 1600 |
| Ask | 0.3168 x 3200 |
| Day's range | 0.2365 - 0.3390 |
| 52-week range | 0.0810 - 5.6000 |
| Volume | |
| Avg. volume | 16,432,331 |
| Market cap | 17.167M |
| Beta (5Y monthly) | 0.41 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.3700 |
| Earnings date | 10 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireKintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results
Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal third quarter ended March 31, 2024, and recent corporate developments.
ZacksKintara (KTRA) Stock Soars on Merger Agreement With TuHURA
Kintara (KTRA) inks a definitive merger agreement with TuHURA for an all-stock transaction. It is expected to close in the third quarter of 2024. The stock surges 63.4%.
- PR Newswire
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement
Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara"), a biopharmaceutical company investigating REM-001 in an NIH-sponsored and funded open label study in cutaneous metastatic breast cancer, and TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that they have entered into a definitive agreement for an all-stock transaction forming a company with expertise and res
